---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-146203"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2023-05-16T23:59:59+00:00"
generated_at: "2026-06-14T23:55:15.259446+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# TScan enters ATM equity offering with Wedbush, up to 2% commission

## Summary
- Entered Sales Agreement with Wedbush Securities for at-the-market issuance of common stock.
- Commission of up to 2.0% of gross proceeds; Company sets sale parameters.
- Shelf registration statement (333-268260) declared effective May 16, 2023; prospectus supplement filed.
- No obligation to sell; either party may suspend or terminate offering on notice.
- Sales may also be made to Wedbush as principal at agreed prices; customary indemnification.

## SEC filing metadata
- accession: 0001193125-23-146203
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2023-05-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000119312523146203/0001193125-23-146203-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000119312523146203/d502216d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-146203
- JSON: https://secwatch.observer/filing/0001193125-23-146203.json
- Plain text: https://secwatch.observer/filing/0001193125-23-146203.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.